WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025, the deal ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million. WuXi had previously said it was planning to sell some of its operations as the ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and expanding its vaccine production capabilities.

News that pharmaceutical company MSD Ireland has acquired the WuXi Vaccines manufacturing facility in Dundalk has been ...

Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

WuXi 2269-1.25%decrease ... The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late ...

WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025 ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...